Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe’s disease

INTRODUCTION: Pompe’s disease is a metabolic myopathy caused by a deficiency of the enzyme alpha-glucosidase. Patients with late-onset Pompe’s disease have progressive muscle weakness, which also affects pulmonary function. Since the advent of specific treatment for Pompe’s disease, enzyme replaceme...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés, Emilia Barrot, Chacón, Juana María Barrera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873020/
https://www.ncbi.nlm.nih.gov/pubmed/24392291
http://dx.doi.org/10.1007/s13554-011-0001-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873020/
https://www.ncbi.nlm.nih.gov/pubmed/24392291
http://dx.doi.org/10.1007/s13554-011-0001-y

Ejemplares similares